DDInter1135 DDInter899
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Meclofenamic acid {u} (Compound) resembles {v} (Compound) Salicylic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Meclofenamic acid {u} (Compound) binds {v} (Gene) ALOX5
Meclofenamic acid {u} (Compound) upregulates {v} (Gene) DMTF1
Meclofenamic acid {u} (Compound) downregulates {v} (Gene) CSRP1
Meclofenamic acid {u} (Compound) causes {v} (Side Effect) Abdominal pain
Meclofenamic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Meclofenamic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Meclofenamic acid {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Meclofenamic acid (Compound) resembles Salicylic acid (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Meclofenamic acid (Compound) binds ALOX5 (Gene)
Meclofenamic acid (Compound) upregulates DMTF1 (Gene)
Meclofenamic acid (Compound) downregulates CSRP1 (Gene)
Meclofenamic acid (Compound) causes Abdominal pain (Side Effect)
Meclofenamic acid may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Meclofenamic acid may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Meclofenamic acid may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan